EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital
Increase
Marinomed Biotech AG resolves capital increase excluding statutory
subscription rights by issuing 154,053 no-par value bearer shares at an
issue price of EUR 5 per share

18-Sep-2024 / 17:21 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS
Group AG.
The issuer is solely responsible for the content of this announcement.

══════════════════════════════════════════════════════════════════════════

Korneuburg, Austria, 18. September 2024 – Marinomed Biotech AG (the
“Company”) announces that the Management Board has resolved today to
increase the Company’s share capital by EUR 154,053 to EUR 1,694,583 by
issuing 154,053 new no-par value bearer shares against cash contributions.
The new shares will be issued from the authorized capital 2024 and are
subject to the direct exclusion of the statutory subscription rights of
existing shareholders. The issue price per new share is EUR 5, so that the
total issue price amounts to EUR 770,265. The Company’s Supervisory Board
approved this capital increase today, immediately after the Management
Board passed the resolution.

All 154,053 new shares have been subscribed at these issue terms and
conditions by a total of eleven investors, including members of the
Supervisory and Management Boards.

The Company is continuing to negotiate with another investor regarding a
possible second capital increase of a further 154,053 new shares to be
issued from the authorized capital 2024, which would be issued in
accordance with the authorization to exclude the statutory subscription
rights of existing shareholders. The actual implementation of this second
capital increase is dependent on the outcome of the specific negotiations
with the investor, the conclusion of the respective transaction documents
and the adoption of a resolution by the Company’s Management Board and
Supervisory Board. For the second capital increase, a report on the
planned exclusion of statutory subscription rights must also be published
at least two weeks before the required Supervisory Board resolution. In
addition, the approval of the restructuring administrator (still pending
for the second capital increase) is required due to the ongoing
restructuring proceedings.

+++ End of ad-hoc announcement +++

End of Inside Information

══════════════════════════════════════════════════════════════════════════

18-Sep-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com

══════════════════════════════════════════════════════════════════════════

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1990689

 
End of Announcement EQS News Service

1990689  18-Sep-2024 CET/CEST